Article
Long-term follow-up of predominantly Asian patients with relapsed/refractory FLT3-mutated acute myeloid leukemia in the phase 3 COMMODORE trial.
Annals of hematology - 12 Jan 2026
Jiang Bin, Li Jian, Liu Ligen, Du Xin, Jiang Hao, Hu Jianda, Zeng Xiaoxi, Sakatani Taishi, Kosako Masanori, Deng Yaru, Ivanov Vladimir, Bondarenko Sergey, Lee Lee Lily Wong, Khuhapinant Archrob, Martynova Elena, Hasabou Nahla, An Jamie Jung-Hee, Wang Jianxiang
Abstract excerpt
To evaluate the long-term efficacy and safety of gilteritinib compared with salvage chemotherapy (SC) in patients with relapsed/refractory FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukemia (AML). In the phase 3 COMMODORE (NCT03182244) trial, patients with relapsed/refractory FLT3-mutated AML from China, Russia, Singapore, Thailand, and Malaysia were randomized to gilteritinib (120 mg/day) or SC....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.